<Blinded Review: TIME_ANON_0598>
OVERALL_SCORE: 5.8/10
VERDICT: CAVEATS
ESTIMATED_DECADE: 2020s
**Composite Score:** 5.8 / 10.0 (Rigor: 1.8/3.5 | Claims: 1.6/2.5 | Biology: 1.4/2.0 | Reproducibility: 1.0/2.0)
**Scientific Core Score:** 4.8 / 8.0
**Bias Category:** Technical/Assay
**Verdict:** Major Revision
**Study Modality:** Wet-Lab Primary Experimental
**Technology Maturity:** Mid-Stage High-Throughput
**Epistemic Stage:** Clinical/Observational

---

### 1. Executive Summary (SUMMARY)
This clinical case report describes the use of preimplantation genetic testing for monogenic disorders (PGT-M) via the MARSALA workflow—combining multiple annealing and looping-based amplification cycles (MALBAC) whole-genome amplification, low-pass next-generation sequencing (~5x coverage) for copy number variation (CNV) calling, SNP haplotyping across 60 informative flanking markers, and targeted Sanger sequencing—to prevent transmission of an X-linked retinoschisis (*RS1* c.187T>C, p.Cys63Arg) variant in a single family. Out of 8 biopsied blastocysts, embryo E1 was selected and transferred, resulting in a healthy female live birth confirmed by mid-trimester amniocentesis. While the clinical workflow (WGA + direct genotyping + flanking SNP linkage + prenatal confirmation) follows established reproductive genetics practice, the manuscript is undermined by severe internal numerical and biological contradictions between the main text, figures, and Table 1 regarding embryo sex chromosome karyotypes and mutation carrier status.

### 2. Methodological & Statistical Audit (STRENGTHS, WEAKNESSES & METHODOLOGICAL AUDIT)
**Strengths:**
* Combines direct mutation detection (Sanger sequencing of *RS1* exon 4) with flanking SNP linkage analysis (within 1–2 Mb upstream and downstream) and 24-chromosome CNV profiling, reducing misdiagnosis risk from allelic dropout (ADO reported as 4.35%).
* Includes mid-trimester amniocentesis verification (chromosomal microarray and Sanger sequencing) and 3-month postnatal ophthalmic follow-up.

**Weaknesses & Methodological Audit:**
* **Direct Contradiction in Embryo E5 Sex Chromosome Genotype (Table 1):** In Table 1, Embryo E5 is listed as `46, XY` under "Copy number variations" (male karyotype) but `normal female` under "SNP haplotype". A euploid embryo cannot simultaneously be `46, XY` and a normal female without sex reversal or genotyping error; this discrepancy is never explained.
* **Direct Contradiction Regarding Embryo E7 and E8 Mutation Status:** In the Discussion (Section "Discussion", paragraph 4), the authors state: *"Through CNV, SNP haplotype, and Sanger sequencing analyses, we confirmed that embryos E1, E4, E5, and E7 did not carry the pathogenic RS1 p.(Cys63Arg) variant or chromosome abnormalities."* This directly contradicts the Results section, Figure 2A, Figure 3, and Table 1, which all report that embryo **E7 carries the pathogenic `c.187T>C` mutation and an abnormal maternal haplotype**, whereas **E8** is non-mutant by Sanger/haplotype (though aneuploid for `+11p`). Furthermore, the Results text ("Blastocyst culture, trophoblast biopsy, and Sanger sequencing") states *"no mutations were detected in E1, E4, E5, or E6"*, omitting E8, even though Figure 2A and Table 1 show E8 is also normal at the *RS1* locus.
* **Contradictory Chromosomal Localization and Variant Nomenclature Typos:** The Introduction correctly places *RS1* on `Xp22.1`, whereas the Discussion states the son is hemizygous *"because of the location on Xq22"*. In the Results ("Patients and relatives"), the variant is miswritten as `c.187C>T` when reporting the REVEL score (0.953), and the RefSeq transcript version oscillates between `NM_000330.4` (Abstract, Discussion) and `NM_000330.3` (Results, Figure 1 legend).
* **Incomplete Reporting of SNP Selection:** The Methods section states that *"30 SNP markers that were located within 2 Mb upstream or downstream of the gene were selected"*, whereas the Results section ("SNP haplotype analysis results") states that *"60 informative polymorphic SNPs were selected, and the analysis focused on 15 SNPs within 1 Mb upstream and downstream"*.

### 3. Biological / Experimental Grounding & Claim Proportionality
* **Identification of *RS1* c.187T>C (p.Cys63Arg) as Likely Pathogenic in the family: [Well Supported].** Pedigree segregation, absence in gnomAD (`PM2_Supporting`), REVEL score of 0.953 (`PP3_Strong`), disruption of the conserved Cys63–Cys219 disulfide bond in the discoidin domain, and specific clinical OCT/fundus phenotype (`PP4`) support the ACMG classification.
* **Successful selection of an unaffected euploid embryo (E1) leading to a healthy live birth: [Well Supported].** Concordant trophectoderm biopsy results, 20-week amniocentesis CMA/Sanger verification, and postnatal examination support the clinical outcome for E1.
* **Accuracy of the reported cohort-wide embryo genotyping table: [Methodologically Flawed].** The discordant `46, XY` vs. `normal female` entries for E5 in Table 1 and the false statement in the Discussion that E7 was mutation-free undermine confidence in data curation.

### 4. Reproducibility & Data Completeness
* **Data Availability:** Raw sequencing data (NGS reads for CNV and SNP haplotyping) are not deposited in any public or controlled-access repository; the manuscript only provides a boilerplate statement that data "will be made available by the authors, without undue reservation."
* **Reagent & Protocol Reporting:** Forward and reverse PCR primers for *RS1* Sanger validation are provided, but the coordinates, rsIDs, and genotypes of the 15–60 flanking SNPs used to construct the haplotypes in Figure 3 are not tabulated.
</Blinded Review: TIME_ANON_0598>
